Moderna Skyrockets Over 60%, Merck Jumps On Late-Stage Cancer Vaccine Trial Win
Moderna skyrocketed and Merck jumped on strong late-stage trial results for their cancer vaccine in melanoma patients Wednesday.
The post Moderna Skyrockets Over 60%, Merck Jumps On Late-Stage Cancer Vaccine Trial Win appeared first on Investor's Business Daily.























































